Last reviewed · How we verify
5-Fluorouracil (5-FU) (5-fluorouracil-5-fu)
5-Fluorouracil (5-FU) inhibits thymidylate synthase, disrupting DNA synthesis and repair in rapidly dividing cells.
At a glance
| Generic name | 5-fluorouracil-5-fu |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Mechanism of action
5-Fluorouracil works by blocking an enzyme called thymidylate synthase, which is crucial for making DNA. This disruption prevents cancer cells from reproducing and spreading.
Approved indications
Common side effects
- Diarrhoea
- Nausea
- DIARRHOEA
- Peripheral sensory neuropathy
- Fatigue
- Neutrophil count decreased
- NAUSEA
- Neutropenia
- Vomiting
- Stomatitis
- Constipation
- Anaemia
Key clinical trials
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (PHASE2)
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (PHASE3)
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
- A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC) (PHASE2)
- Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (PHASE1)
- MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer (PHASE1)
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5-Fluorouracil (5-FU) CI brief — competitive landscape report
- 5-Fluorouracil (5-FU) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI